Visudyne 2 mg/ml Injection

A course of verteporfin therapy is a two-step process requiring administration of both drug and light. The first step is the intravenous infusion of Verteporfin. The second step is the activation of Verteporfin with light from a nonthermal diode laser. The physician should reevaluate the patient 3 months after treatment and if choroidal neovascular leakage is detected on?fluorescein angiography, therapy may be repeated.

Lesion Size Determination: The greatest linear dimension (GLD) of the?lesion?should be estimated by fluorescein?angiography?and color fundus photography. All classic and occult CNV, blood and/or blocked fluorescence, and any serous detachments of the?retinal pigment epithelium should be included for this measurement. Fundus cameras with magnification within the range of 2.4-2.6X are recommended. The GLD of the lesion on the fluorescein angiogram must be corrected for the magnification of the fundus camera to obtain the GLD of the lesion on the?retina.

Spot Size Determination: The treatment spot size should be 1000 microns larger than the GLD of the lesion on the retina to allow a 500 micron border, ensuring full coverage of the lesion. The maximum spot size used in the clinical trials was 6400 microns.

The?nasal?edge of the treatment spot must be positioned at least 200 microns from the temporal edge of the?optic disc, even if this will result in lack of photoactivation of CNV within 200 microns of the?optic nerve.